The intervention trial of safety and efficacy of once-weekly Trelagliptin switched from daily DPP4 inhibitors for elderly patients with type 2 diabetes

The intervention trial of safety and efficacy of once-weekly Trelagliptin switched from daily DPP4 inhibitors for elderly patients with type 2 diabetes - Safety and efficacy of Trelagliptin in elderly patients with type 2 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026319

Enrollment

Registered

2017-03-01

Start date

2017-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Trelagliptin 100 mg will be administered once a week for 12 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes who are administered daily DPP4 inhibitors over 65 years of age

Exclusion criteria

Exclusion criteria: Patients with renal dysfunction [creatinine clearance <50 ml/min or serum creatinine above 1.4 mg/dl(male), 1.2 mg/dl(female)] Patients using insulin or GLP-1 receptor agonists

Design outcomes

Primary

Measure	Time frame
Levels of glycohemoglobin at before and 12 weeks after switching	—

Secondary

Measure	Time frame
Blood pressure, abdominal circumference, weight,frequency and severity of hypoglycemia, liver function, renal function	—

Countries

Japan

Contacts

Public ContactTakahiro Suzuki

Kanagawa-ken Keiyu-kai Keiyu hospital Department of internal medicine

t-suzuki@keiyu-hospital.com045-221-8181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026